Drug Safety Information for ONGLYZA (Saxagliptin hydrochloride)
Safety-related Labeling Changes for ONGLYZA (SAXAGLIPTIN HYDROCHLORIDE) Rx Drug: FDA Link
Required post-approval safety study:
Conduct a 26-week randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the monotherapies saxagliptin and dapagliflozin for the treatment of pediatric patients ages 10 to < 18 years with type 2 diabetes mellitus, followed by a 26-week site- and subject-blinded safety extension period (weeks 26 to 52). Background therapy will consist of either metformin, insulin, or metformin plus insulin. A second randomization will take place at week 14, with uptitration of dose (saxagliptin may be increased from 2.5 mg to 5 mg dapagliflozin from 5 mg to 10 mg) for approximately half of the subjects with a hemoglobin A1C greater than or equal to 7%. Due Date: 2022-04-30
Original FDA Drug Approval Date for ONGLYZA: 2009-07-31
Adverse Drug Reactions for ONGLYZA* (Saxagliptin hydrochloride)
These charts and graphs are based on reports received through the FDA Adverse Event Reporting System (FAERS) program (see below).
Top 20 Adverse Effects Associated with ONGLYZA
(reported in FDA Medwatch/FAERS Reports)
Side Effect | # of FDA Reports | |
---|---|---|
1 | Blood glucose increased | 247 |
2 | Nausea | 244 |
3 | Drug ineffective | 191 |
4 | Pancreatitis | 184 |
5 | Diarrhoea | 170 |
6 | Rash* | 166 |
7 | Headache | 163 |
8 | Vomiting | 145 |
9 | Dizziness | 137 |
10 | Oedema peripheral | 121 |
11 | Weight decreased | 120 |
12 | Fatigue | 117 |
13 | Renal failure acute | 107 |
14 | Hypoglycaemia | 103 |
15 | Pruritus* | 101 |
16 | Dyspnoea | 97 |
17 | Asthenia | 94 |
18 | Abdominal pain | 89 |
19 | Abdominal pain upper | 86 |
20 | Pneumonia | 83 |
* This side effect also appears in "Top 10 Side Effects of ONGLYZA " in the drug's Review Summary based on AskaPatient reviews.
Top 10 Reasons for Taking ONGLYZA
(associated with FDA Medwatch/FAERS Reports)
Reason | # of FDA Reports | |
---|---|---|
1 | Type 2 diabetes mellitus | 3319 |
2 | Diabetes mellitus* | 2402 |
3 | Product used for unknown indication | 875 |
4 | Blood glucose increased | 49 |
5 | Blood glucose abnormal | 48 |
6 | Type 1 diabetes mellitus | 28 |
7 | Blood glucose | 27 |
8 | Hyperglycaemia | 25 |
9 | Diabetes mellitus inadequate control | 23 |
10 | Blood glucose decreased | 18 |
*Also a top-10 reason in AskaPatient Review Summary.
Types of Adverse Events for ONGLYZA
Total Reports Filed with FDA: 11713
Number of FDA Adverse Event Reports by Patient Age for ONGLYZA
Total Reports Filed with FDA: 11713*
* Reports for drugs with the same active ingredients have been aggregated in this analysis: Saxagliptin hydrochloride (Onglyza)
Charts are based on 11713 reports filed with the FDA between 2004 and June 2015.
Adverse Event Reports are submitted to the FDA by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers), health care providers such as doctors (voluntary reporting), and by patients themselves (voluntary reporting). More Information on FDA MedWatch (FDA Safety Information and Adverse Event Reporting Program)Voluntary reporting takes place under the FDA's MedWatch program, where health care professionals and consumers submit reports to FDA when they find a problem with a drug, medical device, biologic, or other FDA-regulated product. An adverse event is any undesirable experience or extreme side effect associated with the use of a medical product. Adverse events include: death, life threatening event, hospitalization, disability or permanent damage, congenital anomaly or birth defect, medical product use requiring a surgical or other intervention, or other serious medical situation believed to be caused by the drug.
Click to go back to search results and ONGLYZA Reviews and Review Summary .
Historical Analytics of FDA Adverse Event Reports Provided by Druginformer.com. FDA Drug Safety Information, including safety-related labeling updates, required post-approval safety studies, risk evaluation management strategies (REMS), alerts, and recalls are compiled by AskaPatient.com from the U.S. Food and Drug Administration.